

Unless otherwise noted, comments regarding each of these applications must be received not later than October 6, 1995.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *FSB Corp.*, Sublette, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of Farmers State Bank of Sublette, Sublette, Illinois.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Area Bancshares Corporation*, Owensboro, Kentucky; to acquire 100 percent of the voting shares of Citizens Deposit Bancshares, Incorporated, Calhoun, Kentucky, and thereby indirectly acquire Citizens Deposit Bank, Calhoun, Kentucky.

Board of Governors of the Federal Reserve System, September 7, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-22707 Filed 9-12-95; 8:45 am]

BILLING CODE 6210-01-F

Keystone Financial Corporation; Acquisition of Company Engaged in Permissible Nonbanking Activities

The organization listed in this notice has applied under § 225.23(a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a

hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than September 27, 1995.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *Keystone Financial Corporation*, Harrisburg, Pennsylvania; to acquire Martindale Andres & Company, Inc., West Conshohocken, Pennsylvania, and thereby engage in investment advisory activities, pursuant to § 225.25(b)(4) of the Board's Regulation Y; and in brokerage activities, pursuant to § 225.25(b)(15) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, September 7, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-22708 Filed 9-12-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee (NVAC), Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines (ACCV) Subcommittee on Vaccine Safety, Subcommittee on Immunization Coverage, and Subcommittee on Future Vaccines: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.–12 noon, September 28, 1995. 8:30 a.m.–1 p.m., September 29, 1995.

Place: Hubert H. Humphrey Building, Room 703A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Committee shall advise and make recommendations to the Director of the

National Vaccine Program on matters related to the Program responsibilities.

Matters To Be Discussed: The Committee will discuss the National Vaccine Program Office operations and staffing; report of the Task Force on Safer Vaccines; status of the Advisory Committee on Immunization Practices reevaluation of polio immunization recommendations; impact of Federal budget cuts on Federal vaccine research; update on the Children's Immunization Initiative, including the Vaccines for Children Program; Mercer Report: next step; update on pertussis trial; status of the Salk facility; impact on welfare reform; subcommittee reports: vaccine safety, immunization coverage, and future vaccines; and a working group report on adult immunization.

Name: Subcommittee on Vaccine Safety and the Advisory Commission on Childhood Vaccines Subcommittee on Vaccine Safety.

Time and Date: 1:30 p.m.–5 p.m., September 28, 1995.

Place: Hubert H. Humphrey Building, Room 337A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This joint ACCV/NVAC subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

Matters To Be Discussed: The Subcommittee will discuss the Institute of Medicine vaccine safety forum and summary of planned workshops; summary of the final report of the task force on safer childhood vaccines; and the charge of the Subcommittees.

Name: Subcommittee on Immunization Coverage.

Time and Date: 1:30 p.m.–5 p.m., September 28, 1995.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Immunization Coverage will identify strategies and policy options by which to further improve the levels of immunization coverage.

Matters To Be Discussed: The Subcommittee will discuss determinants of under vaccination in preschool children; national, State, and local immunization coverage levels; current interventions for immunization and the future health environment.

Name: Subcommittee on Future Vaccines.

Time and Date: 1:30 p.m.–5 p.m., September 28, 1995.

Place: Hubert H. Humphrey Building, Room 425A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

Matters to be Discussed: The Subcommittee will review and discuss the

terms of reference for the Subcommittee; identify the matrix of interactions and partnerships, via specific case studies; describe the process of priority-setting by each of the members of the vaccine research and development community, and define barriers to new vaccine development.

Agenda items for each meeting are subject to change as priorities dictate.

Contact Person for More Information:

Gloria A. Kovach, Committee Management Specialist, National Vaccine Program Office, CDC, 1600 Clifton Road, NE, M/S A20, Atlanta, Georgia 30333, telephone 404/639-3851.

Dated: September 7, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-22693 Filed 9-12-95; 8:45 am]

BILLING CODE 4163-18-M

Public Health Service

Statement of Organization, Functions, and Delegations of Authority

Part H, Public Health Service (PHS), Chapter HA (Office of the Assistant Secretary for Health), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (DHHS) is amended to revise Chapter HA (Office of the Assistant Secretary for Health), and Chapter HC (Centers for Disease Control and Prevention). These revisions will reflect the transfer of responsibility for the National Vaccine Program Office (NVPO) from the Office of the Assistant Secretary for Health (OASH) to the Centers for Disease Control and Prevention (CDC). The Director of the National Vaccine Program (NVP) will continue to be the Assistant Secretary for Health. Specifically:

(1) The statement for the Office of the Assistant Secretary for Health (42 FR 61318, December 2, 1977, as amended most recently at 60 FR 18418, April 11, 1995) is amended to delete the title and statement for the NVPO (HA2). Responsibilities of this office are transferred to CDC. The Director of the NVP will continue to be the Assistant Secretary for Health;

(2) The statement for the Centers for Disease Control and Prevention (HC) (45 FR 69696, October 20, 1980, as amended most recently at 60 FR 17792-95, April 7, 1995) is amended to reflect the transfer of the NVPO from the Office of the Assistant Secretary for Health to the Office of the Director, CDC.

Office of the Assistant Secretary for Health

Under Chapter HA, Office of the Assistant Secretary for Health, HA-10, Organization, delete item 14. and renumber items 15. through 17. as items 14. through 16.

Under Section HA-20, Functions, after the title and statement for the Office on Women's Health (HAW), delete the title and statement in its entirety for the National Vaccine Program Office (HA2).

Under Chapter HA, Section HA-30, Delegations of Authority, add the following:

All delegations and redelegations of authority made to PHS officials which were in effect prior to the effective date of this reorganization will continue in effect in them or their successors, pending further redelegations, provided they are consistent with this reorganization.

Centers for Disease Control and Prevention

Under Part H, Chapter HC, Centers for Disease Control and Prevention, Section HC-B, Organization and Functions, following the title and statement for the CDC Washington Office (HCA6), insert the following title and statement:

National Vaccine Program Office (HCA8). The Office: (1) Advises the Director, CDC, regarding issues and concerns identified with the implementation of the responsibilities of the National Vaccine Program (NVP); (2) develops and provides the Director, CDC, an annual Plan for implementation of the responsibilities of the NVP for submission to the Director, NVP; (3) develops data and conducts analyses of Federal spending on vaccines and vaccine-related activities; (4) provides executive secretary and staff and administrative support to the National Vaccine Advisory Committee; (5) coordinates preparation and submission of the annual National Vaccine Report for transmittal by the Director, CDC, to the Director, NVP; and (6) coordinates CDC's development and preparation of data and information in support of the Director, NVP.

Dated: August 1, 1995.

Donna E. Shalala,

Secretary.

[FR Doc. 95-22640 Filed 9-12-95; 8:45 am]

BILLING CODE 4160-17-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[ES-930-05-1310-020241A]

Information Collection Submitted to the Office of Management and Budget for Review Under the Paperwork Reduction Act

The proposal for the collection of information listed below has been submitted to the Office of Management and Budget for approval under the provisions of the Paperwork Reduction Act (44 U.S.C. Chapter 35). Copies of the proposed collection of information may be obtained by contacting the Bureau's Clearance Officer at the phone number listed below. Comments and suggestions on the proposal should be made directly to the Bureau Clearance Officer and to the Officer of Management and Budget, Paperwork Reduction Project (1004-), Washington, DC 20503, telephone 202-395-7340.

Title: Coalbed Methane (43 CFR Part 3170).

OMB Approval Number: (Not Yet Assigned).

Abstract: The Bureau of Land Management is proposing a new rule at 43 CFR Part 3170 to encourage the development of coalbed methane (CBM) in Affected States where conflict over ownership of the resource exists. The new regulations will establish procedures to: space wells; pool conflicting interests; escrow costs and proceeds attributable to conflicting interests; allow the drilling, stimulation, and abandonment of CBM wells; and provide affected parties with notice and the opportunity to comment or object or both. In order to obtain specific approvals under the regulations, applications would submit information to BLM to demonstrate the orderly and efficient development of CBM while preserving the mineability of coal seams.

Bureau Form Number: None.

Frequency: Occasionally.

Description of Respondents:

Respondents may range from individuals to multi-national corporations.

Estimated Completion Time: 100 hours.

This estimate is based on an "application" defined as submitting all the required information to receive approval to: establish one spacing unit, pool all of the conflicting CBM ownership within the unit, and drill and stimulate one CBM well on the unit.

Annual Responses: Nine.